Topics

Pharmaceutical Industry
FDA approves Amgen heart failure drug Corlanor
FDA approves Amgen heart failure drug Corlanor

Biotech company Amgen Inc. took a key step in its expansion into cardiovascular drugs Wednesday when the Food and Drug Administration approved its heart failure drug for sale in the United States. The drug called ivabradine is an oral medication that treats chronic heart failure by slowing the heart rate. Amgen will sell it under the brand name Corlanor. Amgen obtained the U.S. commercial rights for ivabradine in 2013 from French company Les Laboratoires Servier, which developed the drug and sells it in Europe. Heart failure is a condition in which the heart is weakened and unable to pump enough blood to the body. To compensate for its weakened condition, the heart often speeds up...

Loading